TAI'AN, China, Dec. 23, 2010 /PRNewswire-Asia-FirstCall/
-- China Biologic Products, Inc. (Nasdaq: CBPO, the
"Company"), one of the leading plasma-based biopharmaceutical
companies in the People's Republic of
China, today announced that it has dismissed Frazer Frost,
LLP (Frazer Frost") as the Company's independent registered public
accounting firm and has appointed KPMG in its stead.
The decision to change auditors was not the result of any
disagreement between the Company and Frazer Frost on any matter of
accounting practices, financial statement disclosure, or auditing
scope or procedure. The change was authorized and approved by the
Company's board of directors on December 22,
2010.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products
Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its
equity investment in Xi'an Huitian Blood Products Co., Ltd., is
currently one of the leading plasma-based biopharmaceutical
companies in China. The Company is
a fully integrated biologic products company with plasma
collection, production and manufacturing, research and development,
and commercial operations. The Company's plasma-based
biopharmaceutical products are irreplaceable during medical
emergencies and are used for the prevention and treatment of
various diseases. The Company sells its products to hospitals and
other healthcare facilities in China. For additional information, please see
the Company's website at http://www.chinabiologic.com.
|
Company
Contact:
|
|
|
Mr. Y. Tristan
Kuo
|
|
|
Chief Financial
Officer
|
|
|
China Biologic Products,
Inc.
|
|
|
Tel: +86-538-6202206 in
China
|
|
|
Email:
IR@chinabiologic.com
|
|
|
www.chinabiologic.com
|
|
|
SOURCE China Biologic Products, Inc.